Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)Depreciation ExpenseEBIATOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

InMed Pharmaceuticals (INM) Depreciation & Amortization (IS) (2021 - 2025)

Historic Depreciation & Amortization (IS) for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to $53201.0.

  • InMed Pharmaceuticals' Depreciation & Amortization (IS) changed 0.19% to $53201.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $211461.0, marking a year-over-year decrease of 269.38%. This contributed to the annual value of $212839.0 for FY2025, which is 307.88% down from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Depreciation & Amortization (IS) of $53201.0 as of Q4 2025, which was down 0.19% from $53202.0 recorded in Q3 2025.
  • In the past 5 years, InMed Pharmaceuticals' Depreciation & Amortization (IS) registered a high of $55234.0 during Q4 2023, and its lowest value of $28532.0 during Q3 2021.
  • Over the past 5 years, InMed Pharmaceuticals' median Depreciation & Amortization (IS) value was $53202.0 (recorded in 2024), while the average stood at $51486.0.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Depreciation & Amortization (IS) surged by 7190.52% in 2022, and later tumbled by 497.0% in 2023.
  • Over the past 5 years, InMed Pharmaceuticals' Depreciation & Amortization (IS) (Quarter) stood at $49797.0 in 2021, then decreased by 1.5% to $49049.0 in 2022, then rose by 12.61% to $55234.0 in 2023, then dropped by 3.68% to $53202.0 in 2024, then dropped by 0.0% to $53201.0 in 2025.
  • Its last three reported values are $53201.0 in Q4 2025, $53202.0 for Q3 2025, and $52752.0 during Q2 2025.